-$0.78 EPS Expected for Mirna Therapeutics, Inc. (SYBX) This Quarter
Equities research analysts expect Mirna Therapeutics, Inc. (NASDAQ:SYBX) to post ($0.78) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Mirna Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.79) and the highest estimate coming in at ($0.76). Mirna Therapeutics reported earnings per share of ($2.94) during the same quarter last year, which would suggest a positive year over year growth rate of 73.5%. The business is scheduled to announce its next earnings report on Wednesday, March 21st.
According to Zacks, analysts expect that Mirna Therapeutics will report full year earnings of ($5.42) per share for the current year, with EPS estimates ranging from ($5.58) to ($5.26). For the next year, analysts anticipate that the company will report earnings of ($2.76) per share, with EPS estimates ranging from ($3.35) to ($2.16). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Mirna Therapeutics.
Several analysts have commented on SYBX shares. ValuEngine cut shares of Mirna Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research cut shares of Mirna Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 22nd. Wedbush started coverage on shares of Mirna Therapeutics in a research note on Monday, November 27th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Leerink Swann started coverage on shares of Mirna Therapeutics in a research note on Tuesday, September 19th. They set an “outperform” rating and a $25.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $19.67.
WARNING: This article was reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/0-78-eps-expected-for-mirna-therapeutics-inc-sybx-this-quarter/1775229.html.
About Mirna Therapeutics
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mirna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.